Breast Cancer Clinical Trial
Official title:
A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin, and
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Giving these treatments before surgery may make the tumor smaller and
reduce the amount of normal tissue that needs to be removed. Giving trastuzumab after
surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
docetaxel and lapatinib when given with or without combination chemotherapy and to see how
well they work in treating women with locally advanced, inflammatory, or resectable breast
cancer.
Status | Completed |
Enrollment | 129 |
Est. completion date | July 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed invasive breast cancer meeting the following criteria: - Phase I - Locally advanced or inflammatory disease, or specified subgroup of large operable disease for whom neoadjuvant chemotherapy is appropriate, defined as any 1 of the following: - Clinical stage T4a-d, any N (inflammatory breast carcinoma: tumor mass, breast enlargement, oedema and warmth of the skin are often present but not mandatory for the diagnosis) - Any clinical T, N2 or N3 (ipsilateral supraclavicular nodes) - cT3cN0,1 any estrogen receptor (ER) - cT2cN1 any ER - cT2cN0 ER negative - Presence of bilateral breast cancer is allowed - No bone, liver, or other extensive metastases - Minimal lung, skin, or nodal metastases may be allowed at the discretion of the investigator (phase I only) - Phase II - Locally advanced or inflammatory breast cancer, defined as any 1 of the following: - Clinical T4a-d, any N (inflammatory breast carcinoma: tumor mass, breast enlargement, oedema and warmth of the skin are often present but not mandatory for the diagnosis) - Any clinical T, N2 or N3 (ipsilateral supraclavicular nodes) - And M0 - Bilateral breast cancer is allowed provided only 1 side is HER2-positive - Any large resectable T2 or T3 breast cancers, M0 - HER2-positive disease by immunohistochemistry, fluorescent in situ hybridization, and/or chromogenic in situ hybridization - No CNS involvement - Two frozen trucuts for every core biopsy indicated by the translational research study - Hormone receptor status: - Estrogen receptor- and/or progesterone receptor-positive or negative tumor PATIENT CHARACTERISTICS: - Female - WHO performance status 0-2 - Hemoglobin > 10.0 g/dL - Absolute neutrophil count > 1,500/mm^3 - Platelet count > 100,000/mm^3 - Bilirubin < 1.5 times upper limit of normal (ULN) - AST and ALT < 3 times ULN - Creatinine < 1.5 times ULN - No other malignancies within the past 3 years except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix (phase II) - LVEF normal by MUGA or ECHO - ECG normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception 2 weeks prior to, during, and for 1 month after completion of study treatment - No current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease not requiring therapy as per investigator assessment) - No serious cardiac illness or medical condition within the past 6 months including, but not limited to, any of the following: - History of documented congestive heart failure - High-risk uncontrolled arrhythmias - Angina pectoris requiring antianginal medication - Clinically significant valvular heart disease - Evidence of transmural infarction on ECG - Poorly controlled hypertension, defined as systolic blood pressure (BP) > 180 mm Hg or diastolic BP > 100 mm Hg - Able to swallow and retain oral medication - Accessible for repeat dosing and follow up - No concurrent grapefruit juice - No active or uncontrolled infection - No other serious illness - No malabsorption syndrome - No other medical condition (i.e., history of chronic alcohol abuse, hepatitis, HIV, and/or cirrhosis) - No psychological, familial, sociological, or geographical condition that would preclude study participation PRIOR CONCURRENT THERAPY: - No prior therapy for any cancer, including chemotherapy, radiotherapy, or hormonal therapy for breast cancer (phase I) - No prior epidermal growth factor receptor- or HER2-targeted therapy or antibody therapy (phase I) - More than 10 days since prior and no concurrent CYP3A4 inducers or inhibitors - More than 14 days since prior and no concurrent herbal infusions or dietary supplements - No antacids 1 hour before or after lapatinib ditosylate administration - No other concurrent investigational therapy or anticancer therapy - No concurrent prophylactic antibiotics |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | C.H.U. Sart-Tilman | Liege | |
Belgium | Clinique Sainte Elisabeth | Namur | |
France | Institut Bergonie | Bordeaux | |
France | Institut Bergonié | Bordeaux | |
France | CHRU de Limoges | Limoges | |
France | Centre Leon Berard | Lyon | |
France | CRLC Val D'Aurelle | Montpellier | |
France | Centre Henri Becquerel | Rouen | |
France | Hopital Rene Huguenin - Institut Curie | Saint-Cloud | |
France | Centre Paul Strauss | Strasbourg | |
France | Institut Gustave Roussy | Villejuif | |
Slovenia | The Institute Of Oncology | Ljubljana | |
Switzerland | Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie | Geneve | |
Switzerland | Centre Hospitalier Universitaire Vaudois | Lausanne | |
United Kingdom | Western General Hospital | Edinburgh |
Lead Sponsor | Collaborator |
---|---|
European Organisation for Research and Treatment of Cancer - EORTC | GlaxoSmithKline |
Belgium, France, Slovenia, Switzerland, United Kingdom,
Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D. Neoadjuvant treatment with docetaxel plus lapatin — View Citation
Bonnefoi H, Zaman K, Debled M, Fiche M, Fournier M, Nobahar M, Pierga JY, Koch KM, Bartlett J, Zimmer A, Marreaud S, Bogaerts J, Cameron D. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuva — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I part: Dose limiting toxicity during cycle 1 | during study | Yes | |
Primary | Phase II: Pathological complete response rate | end of study | No | |
Secondary | Phase I: Changes in apoptosis and proliferation markers. | end of Phase I | No | |
Secondary | Phase II: Tolerability, clinical/radiological response rates, breast conserving surgery, pharmacodynamics data | end of study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |